| Literature DB >> 29272893 |
Eric F Martin1,2, Cynthia Levy2.
Abstract
Primary sclerosing cholangitis (PSC) is a chronic, immune-mediated cholestatic liver disease that often progresses to secondary biliary cirrhosis and end-stage liver disease. Short of liver transplantation (LT), there is no effective treatment for PSC. PSC accounts for approximately 5% of total adult LTs in the US and is currently the fifth most common indication for LT. Patient and graft survival for PSC is among the highest for all indications for LT. The main factors that impact outcomes after LT for PSC include biliary strictures, rejection, and recurrence of PSC. Recurrent PSC (rPSC) develops in 20% of LT recipients within 5 years of LT and is associated with negative patient and graft survival. LT is a viable option for recipients who develop rPSC and progress to graft failure. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Entities:
Mesh:
Year: 2017 PMID: 29272893 DOI: 10.1055/s-0037-1608655
Source DB: PubMed Journal: Semin Liver Dis ISSN: 0272-8087 Impact factor: 6.115